The Immune Rejection Problem in Transplantation

Organ transplantation remains one of the most transformative procedures in modern medicine, offering a second chance at life for patients with end-stage organ failure. Yet despite decades of surgical refinement and immunosuppressive drug development, the body’s innate ability to distinguish self from non-self remains the single greatest barrier to long-term transplant success. When a donor organ is placed into a recipient, the immune system can mount a vigorous attack against what it perceives as foreign tissue. This process—immune rejection—is not a single event but a complex cascade of cellular and molecular responses that can unfold over minutes, days, or years.

Acute rejection typically occurs within weeks to months after transplantation and is driven primarily by T cells that recognize donor antigens presented by recipient antigen-presenting cells. Chronic rejection, on the other hand, develops over months to years and involves both cellular and antibody-mediated mechanisms, leading to progressive fibrosis, vasculopathy, and eventual graft failure. To suppress these destructive responses, transplant recipients are prescribed lifelong regimens of immunosuppressive drugs such as calcineurin inhibitors, corticosteroids, and antiproliferative agents. While these medications are effective at reducing rejection rates, they come with a heavy cost: increased susceptibility to infections, higher risks of malignancy, nephrotoxicity, metabolic disturbances, and cardiovascular complications.

The limitations of pharmacological immunosuppression have driven researchers to explore a more fundamental solution—one that addresses the root cause of rejection by modifying the organ itself. By leveraging advances in gene editing, scientists are now working to create immune-evasive organs that can coexist with the recipient’s immune system without triggering a destructive response. This approach has the potential to transform transplantation outcomes, reduce or eliminate the need for immunosuppressive drugs, and expand the pool of usable donor organs.

Gene Editing Technologies Powering the New Frontier

The development of immune-evasive organs has been accelerated by breakthroughs in gene editing tools, particularly CRISPR-Cas9. Unlike earlier methods such as zinc-finger nucleases or TALENs, CRISPR-Cas9 offers unprecedented precision, efficiency, and ease of use. The system consists of a guide RNA that directs the Cas9 nuclease to a specific DNA sequence, where it introduces a double-strand break. The cell’s natural repair mechanisms—non-homologous end joining or homology-directed repair—can then be harnessed to disrupt, replace, or insert genetic material.

Beyond CRISPR-Cas9, newer tools are expanding the possibilities. Base editors allow single nucleotide changes without creating double-strand breaks, reducing the risk of unintended large deletions or rearrangements. Prime editors offer even greater versatility, enabling precise insertions, deletions, and substitutions. These technologies are particularly valuable for transplantation applications, where off-target effects could introduce unwanted mutations that compromise organ function or safety. Researchers are also developing delivery methods specific to whole organs, including ex vivo perfusion systems that allow gene editing to be performed on donor organs outside the body before transplantation.

The ability to edit multiple genes simultaneously is a key advantage for creating immune-evasive organs. Immune recognition involves a network of genes and pathways, and modifying a single target is rarely sufficient to prevent rejection. Multiplex editing—where several genes are edited in a single procedure—enables researchers to dismantle multiple aspects of the immune response in one step. This capability has been demonstrated in both animal models and, increasingly, in human cells and tissues destined for transplantation.

Strategies for Engineering Immune-Evasive Organs

Human Leukocyte Antigen Engineering

The most heavily studied target for immune evasion is the human leukocyte antigen (HLA) system. HLAs are cell surface proteins that present peptide fragments to T cells, allowing the immune system to survey the contents of cells and detect foreign or abnormal proteins. In transplantation, donor HLAs are the primary triggers of T cell-mediated rejection. Each individual inherits a unique set of HLA genes, and the degree of matching between donor and recipient correlates strongly with graft survival.

Scientists are exploring several strategies to modify HLA expression in donor organs. One approach involves knocking out the beta-2 microglobulin gene, which eliminates the expression of HLA class I molecules on the cell surface. This prevents CD8+ killer T cells from recognizing donor cells. However, complete loss of HLA class I can make cells vulnerable to natural killer (NK) cell attack, because NK cells are activated by the absence of self-MHC molecules. To overcome this, researchers have introduced modified HLA molecules that retain the ability to inhibit NK cells while avoiding recognition by recipient T cells. For example, expression of HLA-E or HLA-G—molecules with immunomodulatory properties—can protect edited cells from both T cell and NK cell responses.

Another sophisticated strategy involves replacing donor HLA genes with recipient-specific HLA genes. If a donor organ could be engineered to express the recipient’s own HLA molecules, the immune system would be far less likely to recognize the organ as foreign. This “HLA matching at the genetic level” is technically challenging but increasingly feasible with modern gene editing tools. Early proof-of-concept studies in pigs have shown that replacing pig HLA genes with human equivalents can reduce rejection in non-human primate models.

Modulating Immune Checkpoint and Signaling Pathways

Beyond HLA engineering, researchers are targeting genes involved in immune signaling and checkpoint regulation. The immune response to a transplanted organ depends on a balance between activating and inhibitory signals. By tipping this balance toward inhibition, it is possible to create a local environment that suppresses rejection without systemic immunosuppression.

One approach involves overexpressing immune checkpoint molecules such as PD-L1 and CTLA-4-Ig on the donor organ. PD-L1 binds to the PD-1 receptor on activated T cells, delivering an inhibitory signal that reduces T cell proliferation and cytokine production. When expressed on transplanted tissues, PD-L1 can create a “shield” that protects the graft from immune attack. Similarly, CTLA-4-Ig blocks co-stimulatory signals required for T cell activation, effectively preventing the initiation of an immune response. Dual expression of these molecules has shown synergistic effects in animal models, dramatically prolonging graft survival.

Another target is the complement system, a part of the innate immune response that can cause rapid tissue damage following transplantation. Genes encoding complement regulatory proteins such as CD46, CD55, and CD59 can be overexpressed to protect the organ from complement-mediated injury. These proteins prevent the formation of the membrane attack complex and promote the decay of complement activation products, reducing inflammation and tissue damage.

Xenotransplantation: A Parallel Frontier

The strategies developed for immune-evasive human organs are also being applied to xenotransplantation—the transplantation of organs from other species into humans. Pigs are the most promising source for xenotransplantation due to their anatomical and physiological similarity to humans, but they present additional immunological barriers. In addition to the rejection mechanisms seen in human-to-human transplantation, pig organs carry carbohydrate antigens such as alpha-gal that are recognized by pre-existing human antibodies, leading to hyperacute rejection.

Gene editing has been instrumental in overcoming these barriers. Researchers have created pigs in which multiple genes responsible for producing immunogenic carbohydrate antigens have been knocked out. These “triple-knockout” pigs, combined with the insertion of human complement regulatory proteins and immune checkpoint molecules, have enabled pig organs to survive for months in non-human primates. In 2022, the first human recipient of a gene-edited pig heart received an organ with 10 genetic modifications, including knockouts of three pig carbohydrate antigens and the insertion of six human transgenes. While the patient survived for two months, the case demonstrated both the potential and the remaining challenges of this approach.

Clinical and Translational Progress

The transition from laboratory bench to bedside is underway for several gene editing approaches in transplantation. Early-phase clinical trials are exploring the safety and feasibility of immune-evasive organs, with a focus on kidney and heart transplantation. In addition to whole-organ transplantation, gene editing is being tested in cellular therapies such as islet cell transplantation for diabetes, where immune evasion could protect insulin-producing cells from autoimmune destruction.

A particularly promising avenue is the use of gene editing to create “universal donor” organs that could be transplanted into any recipient without the need for HLA matching or immunosuppression. While this goal remains aspirational, progress in multiplex editing and delivery technologies is bringing it closer to reality. Several biotechnology companies and academic medical centers have initiated programs to develop universal donor pig organs for clinical use, with initial trials expected within the next three to five years.

Regulatory pathways for gene-edited organs are still being defined. The U.S. Food and Drug Administration has provided guidance on the evaluation of xenotransplantation products and gene-edited animal tissues, but the combination of genetic modification and transplantation raises unique regulatory questions. Coordinated efforts between regulators, researchers, and clinicians will be essential to establish safety standards, manufacturing protocols, and long-term monitoring requirements.

Challenges, Risks, and Ethical Dimensions

Off-Target Effects and Genomic Integrity

Despite the precision of modern gene editors, off-target effects remain a significant concern. Unintended edits could disrupt essential genes, activate oncogenes, or create chromosomal rearrangements. In the context of a whole organ, even a low frequency of off-target events could have consequences for organ function or recipient safety. Advances in high-fidelity Cas9 variants and improved guide RNA design have reduced off-target activity, but complete elimination is not yet achievable. Comprehensive genomic characterization—including whole-genome sequencing and structural variant analysis—will be required for each edited organ batch before clinical use.

Immunological Escape and Viral Susceptibility

Immune-evasive modifications may have unintended consequences for pathogen defense. HLA molecules play a critical role in presenting viral antigens to T cells, and their reduction could make the organ more susceptible to viral infections or reactivation of latent viruses. In xenotransplantation, there is also the risk of transmitting porcine endogenous retroviruses (PERVs) to human recipients. Gene editing has been used to inactivate PERVs in pig cells, but the long-term safety and efficacy of this approach in whole organs remain under investigation.

Ethical and Societal Implications

The creation of immune-evasive organs raises profound ethical questions. Informed consent for recipients must include clear communication about the uncertainties and risks associated with gene editing, particularly when the modifications are permanent and heritable in the case of xenotransplantation donor animals. The welfare of genetically modified animals is another concern, as the editing process may have unintended health effects on the donor animals. Ethical frameworks for animal use in xenotransplantation are evolving, with emphasis on minimizing suffering and ensuring that the benefits to human recipients justify the harms to animal donors.

Access and equity are also important considerations. If gene-edited organs prove successful, they are likely to be expensive, at least initially. Ensuring equitable access across populations and health systems will require policy interventions, reimbursement models, and manufacturing scale-up. Without deliberate planning, there is a risk that these innovations could exacerbate existing disparities in transplant access.

Future Directions and Emerging Possibilities

Looking ahead, several trends are likely to shape the field of immune-evasive organ transplantation. Advances in delivery technologies—including lipid nanoparticles, viral vectors, and ex vivo perfusion systems—will enable more efficient and uniform gene editing across whole organs. Single-cell sequencing and spatial transcriptomics will allow researchers to characterize the immune landscape of edited organs in unprecedented detail, identifying potential vulnerabilities and guiding further optimization.

The integration of synthetic biology approaches may also expand the repertoire of immune-evasive strategies. Researchers are exploring the use of genetic “switches” that allow organ immunogenicity to be turned on or off in response to external signals. This would provide a degree of control that is not possible with permanent edits, enabling clinicians to adjust the immune status of a transplanted organ in response to changing conditions.

Long-term outcomes data from early clinical trials will be essential to validate the safety and efficacy of immune-evasive edits. If successful, these approaches could reduce the burden of immunosuppression, improve graft survival, and expand the donor pool through xenotransplantation. The ultimate vision—a future in which organ transplantation is a routine, low-risk procedure without the need for lifelong medication—is ambitious but increasingly within reach.

Collaboration between molecular biologists, transplant surgeons, immunologists, bioethicists, and regulators will be critical to realizing this vision. The field is moving rapidly, and the convergence of gene editing with transplantation science represents one of the most exciting frontiers in regenerative medicine. With careful attention to safety, ethics, and equity, immune-evasive organs have the potential to save countless lives and reshape the landscape of solid organ transplantation for decades to come.